Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Global burden of primary liver cancer in 2020 and predictions to 2040
Harriet Rumgay, Melina Arnold, Jacques Ferlay, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 6, pp. 1598-1606
Open Access | Times Cited: 1052

Showing 1-25 of 1052 citing articles:

Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Yee Hui Yeo, Jamil S. Samaan, Wee Han Ng, et al.
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 3, pp. 721-732
Open Access | Times Cited: 409
Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy
Amit G. Singal, Fasiha Kanwal, Josep M. Llovet
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 12, pp. 864-884
Closed Access | Times Cited: 278
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
Shukui Qin, Minshan Chen, Ann‐Lii Cheng, et al.
The Lancet (2023) Vol. 402, Iss. 10415, pp. 1835-1847
Closed Access | Times Cited: 222
Ferroptosis inducers enhanced cuproptosis induced by copper ionophores in primary liver cancer
Wei‐Kai Wang, Kaizhong Lu, Xin Jiang, et al.
Journal of Experimental & Clinical Cancer Research (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 104
Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Shukui Qin, Masatoshi Kudo, Tim Meyer, et al.
JAMA Oncology (2023) Vol. 9, Iss. 12, pp. 1651-1651
Open Access | Times Cited: 98
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology
Daniel Q. Huang, Amit G. Singal, Fasiha Kanwal, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 12, pp. 797-809
Closed Access | Times Cited: 82
The role of miRNAs in liver diseases: Potential therapeutic and clinical applications
Ahmed S. Doghish, Mohammed S. Elballal, Ola Elazazy, et al.
Pathology - Research and Practice (2023) Vol. 243, pp. 154375-154375
Closed Access | Times Cited: 79
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022
Michel Ducreux, Ghassan K. Abou‐Alfa, Tanios Bekaii‐Saab, et al.
ESMO Open (2023) Vol. 8, Iss. 3, pp. 101567-101567
Open Access | Times Cited: 79
The latest global burden of liver cancer: A past and present threat
Joo Hyun Oh, Dae Won Jun
Clinical and Molecular Hepatology (2023) Vol. 29, Iss. 2, pp. 355-357
Open Access | Times Cited: 64
Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Yee Hui Yeo, Jamil S. Samaan, Wee Han Ng, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 43
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real‐world cohort
Fabian Jost‐Brinkmann, Münevver Demir, Alexander Wree, et al.
Alimentary Pharmacology & Therapeutics (2023) Vol. 57, Iss. 11, pp. 1313-1325
Open Access | Times Cited: 41
Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide
Do Young Kim
Journal of Liver Cancer (2024) Vol. 24, Iss. 1, pp. 622-70
Open Access | Times Cited: 40
Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study
Zhi‐Cheng Jin, Jian-Jia Chen, Xiaoli Zhu, et al.
EClinicalMedicine (2024) Vol. 72, pp. 102622-102622
Open Access | Times Cited: 38
Molecular mechanisms in MASLD/MASH-related HCC
Xiaobo Wang, Liang Zhang, Bingning Dong
Hepatology (2024)
Closed Access | Times Cited: 31
Heterogeneity of hepatocellular carcinoma: from mechanisms to clinical implications
Fatema Safri, Romario Nguyen, Shadi Zerehpooshnesfchi, et al.
Cancer Gene Therapy (2024) Vol. 31, Iss. 8, pp. 1105-1112
Open Access | Times Cited: 23
Trustworthy multi-phase liver tumor segmentation via evidence-based uncertainty
Chuanfei Hu, Tianyi Xia, Ying Cui, et al.
Engineering Applications of Artificial Intelligence (2024) Vol. 133, pp. 108289-108289
Open Access | Times Cited: 22
The Role of TGF-β/SMAD Signaling in Hepatocellular Carcinoma: from Mechanism to Therapy and Prognosis
Xin Xin, Xiyu Cheng, Fanxin Zeng, et al.
International Journal of Biological Sciences (2024) Vol. 20, Iss. 4, pp. 1436-1451
Open Access | Times Cited: 21
Inequities in primary liver cancer in Europe: The state of play
Loreta A. Kondili, Jeffrey V. Lazarus, Peter Jepsen, et al.
Journal of Hepatology (2024) Vol. 80, Iss. 4, pp. 645-660
Open Access | Times Cited: 17
Incidence of liver cancer in young adults according to the Global Burden of Disease database 2019
Pojsakorn Danpanichkul, Majd B. Aboona, Banthoon Sukphutanan, et al.
Hepatology (2024) Vol. 80, Iss. 4, pp. 828-843
Closed Access | Times Cited: 16
Liver Cancer in 2021: Global Burden of Disease Study
En Ying Tan, Pojsakorn Danpanichkul, Jie Ning Yong, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 16
Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed Death-1 inhibitors
Renguo Guan, Nan Zhang, Min Deng, et al.
International Journal of Surgery (2024)
Open Access | Times Cited: 15
Ketocyanine‐Based Fluorescent Probe Revealing the Polarity Heterogeneity of Lipid Droplets and Enabling Accurate Diagnosis of Hepatocellular Carcinoma
Deming He, Minmin Yan, Qiuling Sun, et al.
Advanced Healthcare Materials (2024) Vol. 13, Iss. 7
Closed Access | Times Cited: 14
Minimally Invasive Delivery of Percutaneous Ablation Agent via Magnetic Colloidal Hydrogel Injection for Treatment of Hepatocellular Carcinoma
Wenshu Wu, Xu Yan, Sheng Chen, et al.
Advanced Materials (2024) Vol. 36, Iss. 26
Closed Access | Times Cited: 14
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b–2, study
Richard Finn, Baek‐Yeol Ryoo, Chiun Hsu, et al.
The Lancet Oncology (2025)
Open Access | Times Cited: 4
Donafenib activates the p53 signaling pathway in hepatocellular carcinoma, induces ferroptosis, and enhances cell apoptosis
Jiaming Liang, Meifeng Chen, Guohong Yan, et al.
Clinical and Experimental Medicine (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top